Monoclonal antibody · Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) · developed by Merck &
Vibostolimab is an antibody that binds TIGIT, an inhibitory receptor on tumor-infiltrating T lymphocytes and NK cells, and blocks its interaction with the ligands CD112 and CD155. This frees the costimulatory receptor CD226 to signal and activate anti-tumor T-cell and NK cell responses. It is studied in colorectal cancer, in co-formulation with pembrolizumab.
Summary written with AI from the sources listed at the end of this page.
Colorectal Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →